Connection

Angelo Avogaro to Humans

Back to Details
This is a "connection" page, showing publications Angelo Avogaro has written about Humans.
Angelo Avogaro
Connection Strength
0.213
Humans
  1. Managing diabetes in diabetic patients with COVID: where do we start from? Acta Diabetol. 2021 Nov; 58(11):1441-1450.
    View in: PubMed
    Score: 0.008
  2. Hyperglycemia, glucocorticoid therapy, and outcome of COVID-19. Diabetes Res Clin Pract. 2020 10; 168:108449.
    View in: PubMed
    Score: 0.007
  3. Exposure to dipeptidyl-peptidase-4 inhibitors and COVID-19 among people with type 2 diabetes: A case-control study. Diabetes Obes Metab. 2020 10; 22(10):1946-1950.
    View in: PubMed
    Score: 0.007
  4. Prevalence and impact of diabetes among people infected with SARS-CoV-2. J Endocrinol Invest. 2020 06; 43(6):867-869.
    View in: PubMed
    Score: 0.007
  5. Angiogenic Abnormalities in Diabetes Mellitus: Mechanistic and Clinical Aspects. J Clin Endocrinol Metab. 2019 11 01; 104(11):5431-5444.
    View in: PubMed
    Score: 0.007
  6. One-year caloric restriction and 12-week exercise training intervention in obese adults with type 2 diabetes: emphasis on metabolic control and resting metabolic rate. J Endocrinol Invest. 2019 Dec; 42(12):1497-1507.
    View in: PubMed
    Score: 0.007
  7. Changes in the Prescription of Glucose-Lowering Medications in Patients With Type 2 Diabetes Mellitus After a Cardiovascular Event: A Call to Action From the DATAFILE Study. J Am Heart Assoc. 2019 07 16; 8(14):e012244.
    View in: PubMed
    Score: 0.007
  8. The pleiotropic cardiovascular effects of dipeptidyl peptidase-4 inhibitors. Br J Clin Pharmacol. 2018 08; 84(8):1686-1695.
    View in: PubMed
    Score: 0.006
  9. Insulin treatment in patients with diabetes and heart failure: defendant on the stand. Eur J Heart Fail. 2018 05; 20(5):896-897.
    View in: PubMed
    Score: 0.006
  10. Effects of Hypoglycemia on Circulating Stem and Progenitor Cells in Diabetic Patients. J Clin Endocrinol Metab. 2018 03 01; 103(3):1048-1055.
    View in: PubMed
    Score: 0.006
  11. Counterpoint to the hypothesis that SGLT2 inhibitors protect the heart by antagonizing leptin. Diabetes Obes Metab. 2018 Jun; 20(6):1367-1368.
    View in: PubMed
    Score: 0.006
  12. When metformin is not enough: Pros and cons of SGLT2 and DPP-4 inhibitors as a second line therapy. Diabetes Metab Res Rev. 2018 05; 34(4):e2981.
    View in: PubMed
    Score: 0.006
  13. How to interpret the role of SDF-1a on diabetic complications during therapy with DPP-4 inhibitors. Cardiovasc Diabetol. 2018 02 02; 17(1):22.
    View in: PubMed
    Score: 0.006
  14. p66Shc gene expression in peripheral blood mononuclear cells and progression of diabetic complications. Cardiovasc Diabetol. 2018 01 17; 17(1):16.
    View in: PubMed
    Score: 0.006
  15. Keeping the right track in the treatment of patients with type 2 diabetes. Eur J Heart Fail. 2018 01; 20(1):52-54.
    View in: PubMed
    Score: 0.006
  16. Dipeptidyl peptidase-4 inhibitors moderate the risk of genitourinary tract infections associated with sodium-glucose co-transporter-2 inhibitors. Diabetes Obes Metab. 2018 03; 20(3):740-744.
    View in: PubMed
    Score: 0.006
  17. SGLT2 inhibitors and amputations in the US FDA Adverse Event Reporting System. Lancet Diabetes Endocrinol. 2017 09; 5(9):680-681.
    View in: PubMed
    Score: 0.006
  18. Re: "Plasminogen Activator Inhibitor-1 and Pericardial Fat in Individuals with Type 2 Diabetes Mellitus" by Bayomi et al. (Metab Syndr Relat Disord 2017;15:269-275). Metab Syndr Relat Disord. 2017 08; 15(6):266-268.
    View in: PubMed
    Score: 0.006
  19. SGLT2 inhibitors and diabetic ketoacidosis: data from the FDA Adverse Event Reporting System. Diabetologia. 2017 08; 60(8):1385-1389.
    View in: PubMed
    Score: 0.006
  20. A consensus statement for the clinical use of the renal sodium-glucose co-transporter-2 inhibitor dapagliflozin in patients with type 2 diabetes mellitus. Expert Rev Clin Pharmacol. 2017 Jul; 10(7):763-772.
    View in: PubMed
    Score: 0.006
  21. Effects of the SGLT2 inhibitor dapagliflozin on HDL cholesterol, particle size, and cholesterol efflux capacity in patients with type 2 diabetes: a randomized placebo-controlled trial. Cardiovasc Diabetol. 2017 04 04; 16(1):42.
    View in: PubMed
    Score: 0.006
  22. Dapagliflozin: potential beneficial effects in the prevention and treatment of renal and cardiovascular complications in patients with type 2 diabetes. Expert Opin Pharmacother. 2017 Apr; 18(5):517-527.
    View in: PubMed
    Score: 0.006
  23. The role of point-of-care 3-hydroxybutyrate testing in patients with type 2 diabetes undergoing coronary angiography. J Endocrinol Invest. 2017 Jun; 40(6):627-634.
    View in: PubMed
    Score: 0.006
  24. [Cardiovascular disease in diabetic patients: risk factors, clinical history and prevention]. G Ital Cardiol (Rome). 2016 Dec; 17(12 Suppl 2):3S-12.
    View in: PubMed
    Score: 0.006
  25. Acute Effects of Linagliptin on Progenitor Cells, Monocyte Phenotypes, and Soluble Mediators in Type 2 Diabetes. J Clin Endocrinol Metab. 2016 Feb; 101(2):748-56.
    View in: PubMed
    Score: 0.005
  26. Disentangling conflicting evidence on DPP-4 inhibitors and outcomes of COVID-19: narrative review and meta-analysis. J Endocrinol Invest. 2021 Jul; 44(7):1379-1386.
    View in: PubMed
    Score: 0.002
  27. Efficacy of telemedicine for persons with type 1 diabetes during Covid19 lockdown. Nutr Diabetes. 2021 01 05; 11(1):1.
    View in: PubMed
    Score: 0.002
  28. Cardiac injury and mortality in patients with Coronavirus disease 2019 (COVID-19): insights from a mediation analysis. Intern Emerg Med. 2021 Mar; 16(2):419-427.
    View in: PubMed
    Score: 0.002
  29. The hazard of (sub)therapeutic doses of anticoagulants in non-critically ill patients with Covid-19: The Padua province experience. J Thromb Haemost. 2020 Oct; 18(10):2629-2635.
    View in: PubMed
    Score: 0.002
  30. Newly-diagnosed diabetes and admission hyperglycemia predict COVID-19 severity by aggravating respiratory deterioration. Diabetes Res Clin Pract. 2020 Oct; 168:108374.
    View in: PubMed
    Score: 0.002
  31. Arrhythmic profile and 24-hour QT interval variability in COVID-19 patients treated with hydroxychloroquine and azithromycin. Int J Cardiol. 2020 10 01; 316:280-284.
    View in: PubMed
    Score: 0.002
  32. Pharmacovigilance assessment of the association between Fournier's gangrene and other severe genital adverse events with SGLT-2 inhibitors. BMJ Open Diabetes Res Care. 2019; 7(1):e000725.
    View in: PubMed
    Score: 0.002
  33. Fixed versus flexible combination of GLP-1 receptor agonists with basal insulin in type 2 diabetes: A retrospective multicentre comparative effectiveness study. Diabetes Obes Metab. 2019 11; 21(11):2542-2552.
    View in: PubMed
    Score: 0.002
  34. Effects of exenatide long-acting release on cardiovascular events and mortality in patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Acta Diabetol. 2019 Sep; 56(9):1051-1060.
    View in: PubMed
    Score: 0.002
  35. Ten years of experience with DPP-4 inhibitors for the treatment of type 2 diabetes mellitus. Acta Diabetol. 2019 Jun; 56(6):605-617.
    View in: PubMed
    Score: 0.002
  36. Effects of SGLT2 Inhibitors on Circulating Stem and Progenitor Cells in Patients With Type 2 Diabetes. J Clin Endocrinol Metab. 2018 10 01; 103(10):3773-3782.
    View in: PubMed
    Score: 0.002
  37. Effectiveness of dapagliflozin versus comparators on renal endpoints in the real world: A multicentre retrospective study. Diabetes Obes Metab. 2019 02; 21(2):252-260.
    View in: PubMed
    Score: 0.002
  38. Impaired cognitive processing speed in type 1 diabetic patients who had severe/recurrent hypoglycaemia. J Diabetes Complications. 2018 Nov; 32(11):1040-1045.
    View in: PubMed
    Score: 0.002
  39. Phenotyping normal kidney function in elderly patients with type 2 diabetes: a cross-sectional multicentre study. Acta Diabetol. 2018 Nov; 55(11):1121-1129.
    View in: PubMed
    Score: 0.002
  40. Exposure to insulin degludec during pregnancy: report of a small series and review of the literature. J Endocrinol Invest. 2019 Mar; 42(3):345-349.
    View in: PubMed
    Score: 0.002
  41. Characteristics, prevalence, and outcomes of diabetic foot ulcers in Africa. A systemic review and meta-analysis. Diabetes Res Clin Pract. 2018 Aug; 142:63-73.
    View in: PubMed
    Score: 0.002
  42. Diabetic retinopathy is associated with the presence and burden of subclinical carotid atherosclerosis in type 1 diabetes. Cardiovasc Diabetol. 2018 05 04; 17(1):66.
    View in: PubMed
    Score: 0.002
  43. Use and effectiveness of dapagliflozin in routine clinical practice: An Italian multicentre retrospective study. Diabetes Obes Metab. 2018 07; 20(7):1781-1786.
    View in: PubMed
    Score: 0.002
  44. The antidiabetic drug metformin blunts NETosis in vitro and reduces circulating NETosis biomarkers in vivo. Acta Diabetol. 2018 Jun; 55(6):593-601.
    View in: PubMed
    Score: 0.002
  45. Head-to-head comparison of the accuracy of Abbott FreeStyle Libre and Dexcom G5 mobile. Nutr Metab Cardiovasc Dis. 2018 04; 28(4):425-427.
    View in: PubMed
    Score: 0.002
  46. Assessment of hypoglycaemia during basal insulin therapy: Temporal distribution and risk of events using a predefined or an expanded definition of nocturnal events. Diabetes Metab. 2018 Sep; 44(4):333-340.
    View in: PubMed
    Score: 0.001
  47. FreeStyle Libre and Dexcom G4 Platinum sensors: Accuracy comparisons during two weeks of home use and use during experimentally induced glucose excursions. Nutr Metab Cardiovasc Dis. 2018 02; 28(2):180-186.
    View in: PubMed
    Score: 0.001
  48. miR-30c-5p regulates macrophage-mediated inflammation and pro-atherosclerosis pathways. Cardiovasc Res. 2017 Nov 01; 113(13):1627-1638.
    View in: PubMed
    Score: 0.001
  49. Overnight Closed-Loop Control Improves Glycemic Control in a Multicenter Study of Adults With Type 1 Diabetes. J Clin Endocrinol Metab. 2017 10 01; 102(10):3674-3682.
    View in: PubMed
    Score: 0.001
  50. Shift of monocyte subsets along their continuum predicts cardiovascular outcomes. Atherosclerosis. 2017 Nov; 266:95-102.
    View in: PubMed
    Score: 0.001
  51. Rationale and design of the DARWIN-T2D (DApagliflozin Real World evIdeNce in Type 2 Diabetes): A multicenter retrospective nationwide Italian study and crowdsourcing opportunity. Nutr Metab Cardiovasc Dis. 2017 Dec; 27(12):1089-1097.
    View in: PubMed
    Score: 0.001
  52. Comparison of lower limb muscle strength between diabetic neuropathic and healthy subjects using OpenSim. Gait Posture. 2017 10; 58:194-200.
    View in: PubMed
    Score: 0.001
  53. Sodium-glucose co-transporter-2 inhibitors and diabetic ketoacidosis: An updated review of the literature. Diabetes Obes Metab. 2018 01; 20(1):25-33.
    View in: PubMed
    Score: 0.001
  54. Cognitive, neurophysiologic and metabolic sequelae of previous hypoglycemic coma revealed by hyperinsulinemic-hypoglycemic clamp in type 1 diabetic patients. Metab Brain Dis. 2017 10; 32(5):1543-1551.
    View in: PubMed
    Score: 0.001
  55. Persistent Reduction of Circulating Myeloid Calcifying Cells in Acromegaly: Relevance to the Bone-Vascular Axis. J Clin Endocrinol Metab. 2017 06 01; 102(6):2044-2050.
    View in: PubMed
    Score: 0.001
  56. Intraclass differences in the risk of hospitalization for heart failure among patients with type 2 diabetes initiating a dipeptidyl peptidase-4 inhibitor or a sulphonylurea: Results from the OsMed Health-DB registry. Diabetes Obes Metab. 2017 10; 19(10):1416-1424.
    View in: PubMed
    Score: 0.001
  57. A decade-long telemedicine screening program for diabetic retinopathy in the north-east of Italy. J Diabetes Complications. 2017 Aug; 31(8):1348-1353.
    View in: PubMed
    Score: 0.001
  58. Silent coronary heart disease in patients with type 2 diabetes: application of a screening approach in a follow-up study. J Diabetes Complications. 2017 Jun; 31(6):952-957.
    View in: PubMed
    Score: 0.001
  59. Mechanisms linking empagliflozin to cardiovascular and renal protection. Int J Cardiol. 2017 Aug 15; 241:450-456.
    View in: PubMed
    Score: 0.001
  60. Reduced circulating stem cells associate with excess fasting and post-load NEFA exposure in healthy adults with normal glucose tolerance. Atherosclerosis. 2017 06; 261:117-123.
    View in: PubMed
    Score: 0.001
  61. Influence of health locus of control and fear of hypoglycaemia on glycaemic control and treatment satisfaction in people with Type 1 diabetes on insulin pump therapy. Diabet Med. 2017 05; 34(5):691-697.
    View in: PubMed
    Score: 0.001
  62. Ketone body metabolism in NIDDM. Effect of sulfonylurea treatment. Diabetes. 1992 Aug; 41(8):968-74.
    View in: PubMed
    Score: 0.001
  63. Integrated kinematics-kinetics-plantar pressure data analysis: a useful tool for characterizing diabetic foot biomechanics. Gait Posture. 2012 May; 36(1):20-6.
    View in: PubMed
    Score: 0.001
  64. Carbohydrate and lipid metabolism in cirrhosis. Evidence that hepatic uptake of gluconeogenic precursors and of free fatty acids depends on effective hepatic flow. J Clin Endocrinol Metab. 1984 Jun; 58(6):1125-32.
    View in: PubMed
    Score: 0.000
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.